AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

BLFS · NASDAQ · Medical - Instruments & Supplies

BioLife Solutions

Supplies preservation media and cell-processing tools for cell and gene therapy workflows.

$36.38

After-hours close−0.01 (−0.03%)

At close$36.39(−2.18%)

Something off on this page? Send us feedback.

Profile

BioLife Solutions, Inc.BLFSHealth Care

Sells CryoStor, HypoThermosol, CellSeal, hPL products, and thawing tools used around cell and gene therapy manufacturing. After divesting freezer, biostorage, and logistics assets, the business is focused on recurring biopreservation and cell-processing products.

Provides biopreservation media and cell-processing tools used in cell and gene therapy manufacturing. Current lines include CryoStor and HypoThermosol media, BloodStor, CellSeal containers and fill-finish tools, hPL supplements, and ThawSTAR automated thawing devices.

Usage is tied to therapy developers that need cell integrity across collection, manufacturing, transport, storage, and final-dose handling. Evidence in context is strongest around U.S. clinical-trial use, while company materials frame the workflow as supporting global delivery.

Recent portfolio work moved away from freezer, biostorage, and logistics businesses toward recurring cell-processing consumables. Operations are managed as one reportable segment.

Company facts

CEORoderick de Greef

ListedMar 26, 2014

ExchangeNASDAQ

HeadquartersBothell, WA

CountryUnited States

Employees155

CIK0000834365

ISINUS09062W2044

Key statistics

Market cap$1.78B

EPS (ttm)$1.02

P/E (ttm)35.54

ROE13.3%

P/B4.23

P/S17.29

Dividend yield—

Beta1.17vs XLV 0.88

Year to date +52.3% · Average volume (30d) 1.3M

Analysts

Price target, next 12 months$31.00−14.8%Median of 18 analysts · vs the Aug 28 close

ConsensusBuy12 of 18 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $36.38

High$31.00−14.8%

Median$31.00−14.8%

Low$31.00−14.8%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Prior target	Target
Aug 10, 2026	Benchmark	Downgrade	Buy	Hold
Jul 27, 2026	Stephens	Target			$30	$31
Jul 27, 2026	Stephens & Co.	Downgrade	Overweight	Equal Weight
Jul 23, 2026	Jefferies	Downgrade	Buy	Hold	$22	$31
Jul 23, 2026	H.C. Wainwright	Downgrade	Buy	Neutral	$32	$31

Earnings

EPS

Estimate$0.01

ReportedDue Nov 5, 2026

Revenue

Estimate$29.2M

ReportedDue Nov 5, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 6, 2026Q2 FY26	$0.03	$0.91	+2,812.0%	$27.8M	$28.5M	+2.4%	+2.15%
May 7, 2026Q1 FY26	$0.01	$0.04	+300.0%	$25.7M	$27.5M	+7.2%	−4.67%
Feb 26, 2026Q4 FY25	−$0.02	$0.04	+300.0%	$24.1M	$24.8M	+2.9%	+7.65%
Nov 6, 2025Q3 FY25	$0.00	$0.04	—	$25.7M	$28.1M	+9.3%	−4.03%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$23.9M	$25.4M	$28.1M	$18.8M	$27.5M	$28.5M
Gross profit	$15.8M	$16.4M	$17.9M	$12.7M	$17.4M	$18.3M
Operating income	−$1.2M	−$16.6M	−$89.0K	$5.8M	$27.0K	$1.7M
Net income	−$448.0K	−$15.8M	$621.0K	$3.5M	$1.2M	$45.1M
Diluted EPS	−$0.01	−$0.33	$0.01	$0.08	$0.02	$0.91
Gross margin	65.9%	64.6%	63.9%	67.5%	63.3%	64.2%
Operating margin	-5.1%	-65.5%	-0.3%	31.0%	0.1%	6.0%

Fiscal years (4-quarter sums)FY21 $119.2M · FY22 $161.8M · FY23 $118.2M · FY24 $65.3M · FY25 $96.2M

Revenue by product · FY24

Product$76.0M · 92%

Rental Revenue$6.1M · 7%

Service$160.0K · 0%

Balance sheet, Jun 30, 2026Cash & short-term investments $82.4M · Total debt $15.7M · Total assets $447.5M · Shareholders' equity $420.0M

Dividends

No dividends on record.

Ownership

Institutions 104.47%Insiders 4.00%

A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.

Shares outstanding 48.86M · Float 42.68M · 87.4% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
T. Rowe Price Investment Management, Inc.	6.75M	13.82%	13F	Aug 14, 2026
BlackRock, Inc.	6.38M	13.05%	13F	Aug 7, 2026
Casdin Partners Master Fund, L.P.	4.76M	9.70%	13D	May 22, 2026
Casdin Capital, LLC	4.66M	9.53%	13F	Aug 14, 2026
Invesco Ltd.	2.24M	4.59%	13F	Aug 14, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
May 21, 2026	Casdin Partners Master Fund, L.P.	10 percent owner	−650,000	$23.70
May 20, 2026	Casdin Partners Master Fund, L.P.	10 percent owner	−250,000	$23.70
May 19, 2026	Casdin Partners Master Fund, L.P.	10 percent owner	−300,000	$22.65
Mar 23, 2026	Karen A. Foster	officer: Chief Quality and Operations	−2,577	$19.17
Mar 9, 2026	Karen A. Foster	officer: Chief Quality and Operations	−500	$20.00